SHC Sotera Health

Sotera Health Announces Alex Dimitrief as General Counsel

Sotera Health Announces Alex Dimitrief as General Counsel

Global business leader, distinguished general counsel and big law partner to join Sotera Health

CLEVELAND, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced that Alex Dimitrief is joining the Company as Senior Vice President and General Counsel. Mr. Dimitrief previously served in a variety of senior leadership roles at General Electric (GE), including as President and CEO of General Electric’s Global Growth Organization and as General Counsel of GE. Previously, Mr. Dimitrief was a Partner at Kirkland & Ellis LLP, where he practiced law for twenty years.

“I am thrilled to welcome Alex to the team, and to reunite with a former GE colleague, exceptional legal mind and esteemed business leader,” said Michael B. Petras, Jr., Chairman and Chief Executive Officer of Sotera Health Company. “Alex has deep experience in the governmental, business and legal realms, successfully representing clients in a number of highly visible cases. In addition, Alex’s experience is a unique fit for Sotera Health and I look forward to his keen legal and business leadership.”

At GE, Mr. Dimitrief established a distinguished record of providing steady, pragmatic and effective leadership to steer a broad range of global businesses through complex commercial, legal and organizational challenges. At Kirkland & Ellis, Mr. Dimitrief was nationally-recognized for successful outcomes across a broad scope of highly visible, complex legal matters before federal and state courts throughout the United States and international tribunals. He is a recognized expert in litigation, M&A, corporate governance, regulatory affairs and organizational integrity based on his more than 40 years of experience as a business leader, corporate attorney, law firm partner and White House Fellow.

Mr. Dimitrief also has served on the boards of publicly-traded companies and non-profit organizations, including Ronald McDonald House Charities. He comes to Sotera Health from Zeughauser Group, where Mr. Dimitrief has been advising legal departments and law firms on a broad variety of strategic issues. He is a published author, an adjunct professor at Harvard Law School and New York University Law School and sought-after speaker.

“I am excited to join Michael and the leadership team at Sotera Health,” said Alex Dimitrief. “It will be a privilege to join and represent Sotera Health in its mission-critical work and to do my part to ensure that justice is served based on evidence, science and the rule of law.”

Mr. Dimitrief succeeds Terry Hammons, who left the company for personal reasons. Matthew J. Klaben, who had been serving as interim General Counsel, will return to his role as Deputy General Counsel and remains co-chair of the Company’s ESG Committee. Mr. Dimitrief becomes a member of the Executive team, reporting directly to Chairman and CEO, Michael B. Petras, Jr.

About Sotera Health

Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

Updates can be found from time to time on recent developments in matters relevant to investors on the Investor Relations section of the Company’s website at . For developments related to Ethylene Oxide, updates can be found at .

Contacts 
Jason Peterson

Vice President & Treasurer, Sotera Health



Sally J. Curley, IRC

Curley Global IR, LLC

  
Kristin Gibbs

Chief Marketing Officer, Sotera Health

 

Source: Sotera Health Company



EN
02/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sotera Health

 PRESS RELEASE

Sotera Health Reports First-Quarter 2025 Results

Sotera Health Reports First-Quarter 2025 Results Q1 2025 net revenues increased 2.6% to $255 million, compared to Q1 2024, or 4.4% on a constant currency basisQ1 2025 net loss of $13 million or $0.05 per diluted share, compared to net income of $6 million or $0.02 per diluted share in Q1 2024Q1 2025 Adjusted EBITDA(1) increased 8.8% to $122 million, compared to Q1 2024, or 11.2% on a constant currency basisQ1 2025 Adjusted EPS(1) of $0.14, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.13 in Q1 2024Company reaffirms full-year 2025 outlook of 4.0% - 6.0% net revenues ...

 PRESS RELEASE

Sotera Health Announces First-Quarter 2025 Earnings Release Date

Sotera Health Announces First-Quarter 2025 Earnings Release Date CLEVELAND, April 17, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the first-quarter ended March 31, 2025 before the market opens on Thursday, May 1, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company’s financial results and operatin...

 PRESS RELEASE

Nelson Labs Launches Innovative Rapid Sterility Testing to Significant...

Nelson Labs Launches Innovative Rapid Sterility Testing to Significantly Expedite Product Sterility Results Rapid Sterility Testing yields product sterility test results in as little as 6 days and can be used for broadscale medical device and pharmaceutical product application SALT LAKE CITY, March 04, 2025 (GLOBE NEWSWIRE) -- Nelson Labs, a Sotera Health company and a global leader in microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries, now performs product-sterility testing through rapid microbiological methods (R...

 PRESS RELEASE

Sotera Health Reports Fourth-Quarter and Full-Year 2024 Results; Provi...

Sotera Health Reports Fourth-Quarter and Full-Year 2024 Results; Provides 2025 Outlook 2024 net revenues increased 4.9% to $1.10 billion, compared to 2023; or 5.4% on a constant currency basis2024 net income of $44 million or $0.16 per diluted share, compared to 20232024 Adjusted EBITDA(1) increased 3.9% to $549 million, compared to 2023; or 4.6% on a constant currency basis2024 Adjusted EPS(1) of $0.70, a decrease of $0.02 per diluted share, compared to 2023Full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis C...

 PRESS RELEASE

Sotera Health Announces Fourth-Quarter and Full-Year 2024 Earnings Rel...

Sotera Health Announces Fourth-Quarter and Full-Year 2024 Earnings Release Date CLEVELAND, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2024 before the market opens on Thursday, February 27, 2025. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Compan...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch